AOD-9604
Also known as Anti-Obesity Drug 9604, hGH fragment analog, modified 176-191 fragment
AOD-9604 is a modified C-terminal fragment analog of growth hormone — a distinct lineage from the incretin peptides. A research-use profile: its fragment origin, chemistry, and handling.
AOD-9604 does not belong to the incretin story at all, and that is the most important thing to understand about it. Rather than being an engineered signaling analog like the GLP-1 or amylin compounds, it is a small piece cut from a much larger molecule — a fragment of the C-terminal end of human growth hormone, slightly modified.
It sits in the metabolic-research shelf because of that lineage, but structurally it has more in common with growth-hormone fragment research than with the receptor-agonist analogs it shares a category page with. As with everything on this store, it is described here only as a research compound, with no therapeutic, dosing, or efficacy claims of any kind.
A short synthetic peptide derived from the C-terminal region of the human growth hormone molecule — specifically an analog of the 176-191 fragment, with a small modification (a tyrosine added at the N-terminus) that distinguishes it from the plain fragment. It is a fragment lineage, not an incretin or an amylin analog. Described strictly as a research compound.
A fragment, not a full analog
Human growth hormone is a large protein. Decades of research have looked at whether short regions of that protein carry activity of their own when isolated. AOD-9604 comes from that line of work: it is an analog of the C-terminal 176-191 region of growth hormone, produced synthetically as a short peptide rather than extracted from the whole molecule.
The 'AOD' name (Anti-Obesity Drug) reflects the research program it originated in — a historical label, not an endorsement of any use. What is verifiable and worth stating is the lineage: a growth-hormone fragment, isolated and studied on its own.
What the modification is
AOD-9604 is not the bare 176-191 fragment; it carries a small structural modification, most commonly described as an added tyrosine residue at the N-terminus. That tweak is what makes it an analog of the fragment rather than the fragment itself, and it is the kind of detail worth checking against a certificate of analysis when comparing lots.
This puts it in a family with other growth-hormone-fragment research peptides, distinct from the secretagogue peptides (which prompt the body's own growth-hormone axis) and entirely separate from the incretin and amylin analogs elsewhere in this category.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized. Kept sealed and cold, reconstituted with bacteriostatic water only when a research protocol requires it and then refrigerated. Handled per accepted laboratory practice. Research use only.
Verify a certificate by lot →Common questions
No. It is a modified C-terminal fragment analog of human growth hormone — a completely different lineage from the incretin and amylin analogs it shares a metabolic category with. This is a class description, not a use claim.
It carries a small modification — most commonly described as an added tyrosine at the N-terminus — which makes it an analog of the fragment rather than the unmodified fragment itself.
It stands for 'Anti-Obesity Drug,' a historical label from the research program it originated in. It is a name, not a statement of use; this monograph makes no such claims.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.